Forecast: Diabetes Medicine Use in Finland

The diabetes medicine use in Finland has shown a steady upward trend from 2013 to 2023, with actual data indicating a notable increase from 85.9 units per thousand persons per day in 2013 to 111.9 units in 2023. The year-on-year growth rate has experienced fluctuations, peaking in 2019 and displaying a consistent rise since 2017, excluding a minor dip in 2017. The average annual growth rate (CAGR) over the last five years has been 3.16%, indicative of a robust demand trend.

Looking ahead, the forecasted data from 2024 to 2028 suggests continued growth, albeit at a slightly lower average annual rate of 2.02%. Key drivers for this projected increase include the rising prevalence of diabetes, improved diagnosis rates, and advances in diabetes management technology. The anticipated 10.52% growth over the next five years underscores the market's potential expansion.

Future trends to watch for:

• Innovation in diabetes treatments, including new drug formulations.
• Impacts of healthcare policy changes on medication accessibility.
• Increasing emphasis on preventive care and lifestyle modifications among diabetics.
• Developments in personalized medicine and digital health interventions.